Bicillin Cr Injection, Suspension
NDC Package 60793-600-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Bicillin Cr (penicillin g benzathine and penicillin g procaine) injection is to reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. This formulation utilizes a injection, suspension delivery system. Marketed by Pfizer Laboratories Div Pfizer Inc, this product is identified by NDC 60793-600 and is authorized under FDA application NDA050138.

Identification & Billing

NDC Package Code
60793-600-10
Package Description
10 SYRINGE in 1 PACKAGE / 2 mL in 1 SYRINGE (60793-600-02)
Product Code
60793-600
11-Digit Billing Format
60793060010
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 731538 - penicillin G benzathine / penicillin G procaine 1,200,000 UNT (600,000 UNT/ 600,000 UNT) in 2 ML Prefilled Syringe
  • RxCUI: 731538 - 2 ML penicillin G benzathine 300000 UNT/ML / penicillin G procaine 300000 UNT/ML Prefilled Syringe
  • RxCUI: 731538 - penicillin G benzathine 600,000 UNT / penicillin G procaine 600000 UNT per 2 ML Prefilled Syringe
  • RxCUI: 731541 - BICILLIN C-R 1,200,000 UNT in 2 ML Prefilled Syringe
  • RxCUI: 731541 - 2 ML penicillin G benzathine 300000 UNT/ML / penicillin G procaine 300000 UNT/ML Prefilled Syringe [Bicillin]

Clinical Specifications

Proprietary Name
Bicillin Cr
Non-Proprietary Name
Penicillin G Benzathine And Penicillin G Procaine
Substance Name
Penicillin G Benzathine; Penicillin G Procaine
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
Pharmacologic Class
Usage Information
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response.Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients:Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci.NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia.Moderately severe pneumonia and otitis media due to susceptible Streptococcus pneumoniae.NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage.When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta.

Regulatory & Marketing

Labeler Name
Pfizer Laboratories Div Pfizer Inc
Product Type
Human Prescription Drug
FDA Application #
NDA050138
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-18-1953
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0558
Source: ASP
Peng benzathine/procaine inj
HCPCS Dosage 100,000 UNITS
Units / Pkg 120

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60793-600-10 identifies a specific commercial package of 10 syringe in 1 package / 2 ml in 1 syringe (60793-600-02) of Bicillin Cr, a human prescription drug labeled by Pfizer Laboratories Div Pfizer Inc. This injection, suspension is formulated for intramuscular use and contains penicillin g benzathine; penicillin g procaine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pfizer Laboratories Div Pfizer Inc on May 18, 1953. The current certification is valid through December 31, 2027.

How is this Pfizer Laboratories Div Pfizer Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60793060010. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
60793-600-10
11-Digit CMS (5-4-2)
60793-0600-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.